Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Sigilon Therapeutics to Present at Upcoming September Conferences

Sigilon Therapeutics
Posted on: 07 Sep 17
Sigilon Therapeutics to Present at Upcoming September Conferences

PR Newswire

CAMBRIDGE, Mass., Sept. 7, 2017

CAMBRIDGE, Mass., Sept. 7, 2017 /PRNewswire/ -- Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced the company will present at the following conferences in September.

24th Annual BioCentury NewsMakers in the Biotech Industry Conference

Presenter:

Devyn Smith, Ph.D., Sigilon Therapeutics Chief Strategy Officer and Head of Operations

Date:

Friday, Sept. 8, 2017

Time:

11 a.m. EDT

Location:

Millennium Broadway Hotel, New York

GTCbio 4th Cell & Gene Therapy (CGT) Conference

Title:

Next Generation Cell Therapies – Will These Revolutionize Healthcare?

Presenter:

Devyn Smith, Ph.D., Sigilon Therapeutics Chief Strategy Officer and Head of Operations

Date:

Monday, Sept. 11, 2017

Time:

11:10 a.m. EDT

Location:

Hyatt Regency Boston

15th Annual International Nanomedicine & Drug Delivery Symposium

Title:

Immune Modulatory Biomaterials for Cell-Based Therapies

Presenter:

Omid Veiseh, Ph.D., Sigilon Therapeutics Co-Founder

Date:

Saturday, Sept. 23, 2017

Time:

3 p.m. EDT

Location:

BSRB Kahn Auditorium, University of Michigan, Ann Arbor, Michigan

About Sigilon Therapeutics

Sigilon Therapeutics is developing treatments for chronic diseases using new biomaterials developed at the Massachusetts Institute of Technology that can shield implanted cells from immune attack. Treatments based on Sigilon Therapeutics' technology platform include cell implants that act as "protein factories" and responsive "living therapeutics," providing more natural control for diseases that are currently treated with intermittent injection or infusion. Initial areas of focus include hematologic, enzyme deficiency, endocrine and metabolic disorders. More natural control would restore health and free patients from the need for therapies that are disruptive to quality of life.

For more information please visit www.sigilon.com or follow us on Twitter at https://twitter.com/Sigilon_Inc.

 

View original content:http://www.prnewswire.com/news-releases/sigilon-therapeutics-to-present-at-upcoming-september-conferences-300515399.html

SOURCE Sigilon Therapeutics

PR Newswire
www.prnewswire.com

Last updated on: 07/09/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.